RecruitMe Clinical Trial

ADVL1614: A PHASE 1/2 STUDY OF VX15/2503 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Study of VX15/2508 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Sponsor:Children's Oncology Group COG
Enrolling:Male and Female Patients
Age Range:Between 1 and 30 years old
IRB Number:AAAR7408
U.S. Government ID:NCT03320330
Contact: Rebecca Zylber, NP: 212-305-7212 / rjv2107@cumc.columbia.edu
Additional Study Information:

This is a Phase 1/2 multicenter study of VX15/2503 in pediatric patients and young adults with solid tumors which have come back or have not responded to standard therapy. The study treatment is considered experimental because VX15/2503 is not approved by the United States (US) Food and drug Administration (FDA) for treating pediatric patients and young adults with refractory solid tumors. The purpose of this study is to learn what kind of side effects VX15/2503 can cause and to find the highest safe dose of VX15/2503 that can be given without causing severe side effects. Another goal is to determine whether VX15/2503 is a beneficial treatment for osteosarcoma which has come back or has not responded to standard therapy. VX15/2503 will be administered as an intravenous infusion on Days 1 and 15 of a 28-day period. This entire 28-day period is called a cycle. Patients may continue to receive VX15/2503 for up to about 12 months. Blood samples will be collected to determine how much VX15/2503 is in the blood during the study (pharmacokinetics). Disease assessment will be completed before beginning treatment, at the end of Cycle 1 and then every other cycle.

Do You Qualify?
Has your child been diagnosed with recurrent or refractory solid tumors or osteosarcoma?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Rebecca Zylber, NP
Email: rjv2107@cumc.columbia.edu
Phone: 212-305-7212